S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:ARCT

Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

$33.77
+0.91 (+2.77%)
(As of 03/28/2024 ET)
Today's Range
$32.00
$33.84
50-Day Range
$31.72
$42.99
52-Week Range
$17.52
$43.81
Volume
527,835 shs
Average Volume
443,642 shs
Market Capitalization
$909.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.71

Arcturus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
70.9% Upside
$57.71 Price Target
Short Interest
Bearish
17.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Arcturus Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$910,434 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.42) to $5.10 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.45 out of 5 stars

Medical Sector

535th out of 938 stocks

Pharmaceutical Preparations Industry

241st out of 422 stocks

ARCT stock logo

About Arcturus Therapeutics Stock (NASDAQ:ARCT)

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

ARCT Stock Price History

ARCT Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
ARCT Apr 2024 30.000 call
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
Recap: Arcturus Therapeutics Q4 Earnings
ARCT Sep 2024 30.000 put
Earnings Preview: Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc (ARCT)
See More Headlines
Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARCT
Fax
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$61.33
High Stock Price Target
$90.00
Low Stock Price Target
$45.00
Potential Upside/Downside
+70.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-29,730,000.00
Pretax Margin
-16.72%

Debt

Sales & Book Value

Annual Sales
$169.93 million
Book Value
$10.42 per share

Miscellaneous

Free Float
23,201,000
Market Cap
$909.09 million
Optionable
Optionable
Beta
2.64
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Joseph E. Payne M.Sc. (Age 52)
    Founder, President, CEO & Director
    Comp: $1.13M
  • Mr. Andrew H. Sassine MBA (Age 60)
    CFO & Director
    Comp: $826.88k
  • Ms. Neda Safarzadeh
    Vice President and Head of IR/PR & Marketing
  • Mr. Lance Kurata
    Chief Legal Officer
  • Ms. Natash O. Bowman
    Chief Human Resources Officer
  • Mr. Kevin T. Skol
    Chief Business Officer
  • Dr. Juergen Froehlich FCPh (Age 68)
    M.D., MBA, Chief Medical Officer
  • Dr. Igor Smolenov M.D.
    Ph.D., Chief Development Officer

ARCT Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcturus Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARCT shares.
View ARCT analyst ratings
or view top-rated stocks.

What is Arcturus Therapeutics' stock price target for 2024?

7 analysts have issued 1 year price targets for Arcturus Therapeutics' shares. Their ARCT share price targets range from $36.00 to $90.00. On average, they predict the company's share price to reach $57.71 in the next year. This suggests a possible upside of 70.9% from the stock's current price.
View analysts price targets for ARCT
or view top-rated stocks among Wall Street analysts.

How have ARCT shares performed in 2024?

Arcturus Therapeutics' stock was trading at $31.53 on January 1st, 2024. Since then, ARCT shares have increased by 7.1% and is now trading at $33.77.
View the best growth stocks for 2024 here
.

When is Arcturus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ARCT earnings forecast
.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its earnings results on Monday, November, 8th. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts' consensus estimates of ($1.40) by $0.65. The biotechnology company had revenue of $2.44 million for the quarter, compared to analysts' expectations of $26.70 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative trailing twelve-month return on equity of 18.22%. During the same quarter in the previous year, the company posted ($0.92) earnings per share.

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (7.66%), Vanguard Group Inc. (5.46%), Vanguard Group Inc. (5.46%), Sumitomo Mitsui Trust Holdings Inc. (4.94%), Nikko Asset Management Americas Inc. (4.94%) and Dimensional Fund Advisors LP (4.08%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends
.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARCT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners